Cargando…
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
BACKGROUND: In 2017, Massachusetts General Hospital implemented the Severe Immunotherapy Complications (SIC) Service, a multidisciplinary care team for patients hospitalized with immune-related adverse events (irAEs), a unique spectrum of toxicities associated with immune checkpoint inhibitors (ICIs...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454442/ https://www.ncbi.nlm.nih.gov/pubmed/34544895 http://dx.doi.org/10.1136/jitc-2021-002886 |
_version_ | 1784570494120361984 |
---|---|
author | Zubiri, Leyre Molina, Gabriel E Mooradian, Meghan J Cohen, Justine Durbin, Sienna M Petrillo, Laura Boland, Genevieve M Juric, Dejan Dougan, Michael Thomas, Molly F Faje, Alex T Rengarajan, Michelle Guidon, Amanda C Chen, Steven T Okin, Daniel Medoff, Benjamin D Nasrallah, Mazen Kohler, Minna J Schoenfeld, Sara R Leaf, Rebecca K Sise, Meghan E Neilan, Tomas G Zlotoff, Daniel A Farmer, Jocelyn R Bardia, Aditya Sullivan, Ryan J Blum, Steven M Semenov, Yevgeniy R Villani, Alexandra-Chloé Reynolds, Kerry L |
author_facet | Zubiri, Leyre Molina, Gabriel E Mooradian, Meghan J Cohen, Justine Durbin, Sienna M Petrillo, Laura Boland, Genevieve M Juric, Dejan Dougan, Michael Thomas, Molly F Faje, Alex T Rengarajan, Michelle Guidon, Amanda C Chen, Steven T Okin, Daniel Medoff, Benjamin D Nasrallah, Mazen Kohler, Minna J Schoenfeld, Sara R Leaf, Rebecca K Sise, Meghan E Neilan, Tomas G Zlotoff, Daniel A Farmer, Jocelyn R Bardia, Aditya Sullivan, Ryan J Blum, Steven M Semenov, Yevgeniy R Villani, Alexandra-Chloé Reynolds, Kerry L |
author_sort | Zubiri, Leyre |
collection | PubMed |
description | BACKGROUND: In 2017, Massachusetts General Hospital implemented the Severe Immunotherapy Complications (SIC) Service, a multidisciplinary care team for patients hospitalized with immune-related adverse events (irAEs), a unique spectrum of toxicities associated with immune checkpoint inhibitors (ICIs). This study’s objectives were to evaluate the intervention’s (1) effect on patient outcomes and healthcare utilization, and (2) ability to collect biological samples via a central infrastructure, in order to study the mechanisms responsible for irAEs. METHODS: A hospital database was used to identify patients who received ICIs for a malignancy and were hospitalized with severe irAEs, before (April 2, 2016–October 3, 2017) and after (October 3, 2017–October 24, 2018) SIC Service initiation. The primary outcome was readmission rate after index hospitalization. Secondary outcomes included length of stay (LOS) for admissions, corticosteroid and non-steroidal second-line immunosuppression use, ICI discontinuation, and inpatient mortality. RESULTS: In the pre-SIC period, 127 of 1169 patients treated with ICIs were hospitalized for irAEs; in the post-SIC period, 122 of 1159. After SIC service initiation, reductions were observed in irAE readmission rate (14.8% post-SIC vs 25.9% pre-SIC; OR 0.46; 95% CI 0.22 to 0.95; p=0.036) and readmission LOS (median 6 days post-SIC vs 7 days pre-SIC; 95% CI −16.03 to –0.14; p=0.046). No significant pre-initiation and post-initiation differences were detected in corticosteroid use, second-line immunosuppression, ICI discontinuation, or inpatient mortality rates. The SIC Service collected 789 blood and tissue samples from 234 patients with suspected irAEs. CONCLUSIONS: This is the first study to report that establishing a highly subspecialized care team focused on irAEs is associated with improved patient outcomes and reduced healthcare utilization. Furthermore, the SIC Service successfully integrated blood and tissue collection safety into routine care. |
format | Online Article Text |
id | pubmed-8454442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84544422021-10-13 Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer Zubiri, Leyre Molina, Gabriel E Mooradian, Meghan J Cohen, Justine Durbin, Sienna M Petrillo, Laura Boland, Genevieve M Juric, Dejan Dougan, Michael Thomas, Molly F Faje, Alex T Rengarajan, Michelle Guidon, Amanda C Chen, Steven T Okin, Daniel Medoff, Benjamin D Nasrallah, Mazen Kohler, Minna J Schoenfeld, Sara R Leaf, Rebecca K Sise, Meghan E Neilan, Tomas G Zlotoff, Daniel A Farmer, Jocelyn R Bardia, Aditya Sullivan, Ryan J Blum, Steven M Semenov, Yevgeniy R Villani, Alexandra-Chloé Reynolds, Kerry L J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: In 2017, Massachusetts General Hospital implemented the Severe Immunotherapy Complications (SIC) Service, a multidisciplinary care team for patients hospitalized with immune-related adverse events (irAEs), a unique spectrum of toxicities associated with immune checkpoint inhibitors (ICIs). This study’s objectives were to evaluate the intervention’s (1) effect on patient outcomes and healthcare utilization, and (2) ability to collect biological samples via a central infrastructure, in order to study the mechanisms responsible for irAEs. METHODS: A hospital database was used to identify patients who received ICIs for a malignancy and were hospitalized with severe irAEs, before (April 2, 2016–October 3, 2017) and after (October 3, 2017–October 24, 2018) SIC Service initiation. The primary outcome was readmission rate after index hospitalization. Secondary outcomes included length of stay (LOS) for admissions, corticosteroid and non-steroidal second-line immunosuppression use, ICI discontinuation, and inpatient mortality. RESULTS: In the pre-SIC period, 127 of 1169 patients treated with ICIs were hospitalized for irAEs; in the post-SIC period, 122 of 1159. After SIC service initiation, reductions were observed in irAE readmission rate (14.8% post-SIC vs 25.9% pre-SIC; OR 0.46; 95% CI 0.22 to 0.95; p=0.036) and readmission LOS (median 6 days post-SIC vs 7 days pre-SIC; 95% CI −16.03 to –0.14; p=0.046). No significant pre-initiation and post-initiation differences were detected in corticosteroid use, second-line immunosuppression, ICI discontinuation, or inpatient mortality rates. The SIC Service collected 789 blood and tissue samples from 234 patients with suspected irAEs. CONCLUSIONS: This is the first study to report that establishing a highly subspecialized care team focused on irAEs is associated with improved patient outcomes and reduced healthcare utilization. Furthermore, the SIC Service successfully integrated blood and tissue collection safety into routine care. BMJ Publishing Group 2021-09-20 /pmc/articles/PMC8454442/ /pubmed/34544895 http://dx.doi.org/10.1136/jitc-2021-002886 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Clinical/Translational Cancer Immunotherapy Zubiri, Leyre Molina, Gabriel E Mooradian, Meghan J Cohen, Justine Durbin, Sienna M Petrillo, Laura Boland, Genevieve M Juric, Dejan Dougan, Michael Thomas, Molly F Faje, Alex T Rengarajan, Michelle Guidon, Amanda C Chen, Steven T Okin, Daniel Medoff, Benjamin D Nasrallah, Mazen Kohler, Minna J Schoenfeld, Sara R Leaf, Rebecca K Sise, Meghan E Neilan, Tomas G Zlotoff, Daniel A Farmer, Jocelyn R Bardia, Aditya Sullivan, Ryan J Blum, Steven M Semenov, Yevgeniy R Villani, Alexandra-Chloé Reynolds, Kerry L Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer |
title | Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer |
title_full | Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer |
title_fullStr | Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer |
title_full_unstemmed | Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer |
title_short | Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer |
title_sort | effect of a multidisciplinary severe immunotherapy complications service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer |
topic | Clinical/Translational Cancer Immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454442/ https://www.ncbi.nlm.nih.gov/pubmed/34544895 http://dx.doi.org/10.1136/jitc-2021-002886 |
work_keys_str_mv | AT zubirileyre effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT molinagabriele effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT mooradianmeghanj effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT cohenjustine effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT durbinsiennam effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT petrillolaura effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT bolandgenevievem effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT juricdejan effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT douganmichael effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT thomasmollyf effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT fajealext effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT rengarajanmichelle effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT guidonamandac effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT chenstevent effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT okindaniel effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT medoffbenjamind effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT nasrallahmazen effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT kohlerminnaj effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT schoenfeldsarar effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT leafrebeccak effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT sisemeghane effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT neilantomasg effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT zlotoffdaniela effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT farmerjocelynr effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT bardiaaditya effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT sullivanryanj effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT blumstevenm effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT semenovyevgeniyr effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT villanialexandrachloe effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer AT reynoldskerryl effectofamultidisciplinarysevereimmunotherapycomplicationsserviceonoutcomesforpatientsreceivingimmunecheckpointinhibitortherapyforcancer |